RU2014116566A - MEANS ON THE BASIS OF DEHYDROEPIANDROSTERONE, METHOD OF ITS APPLICATION - Google Patents

MEANS ON THE BASIS OF DEHYDROEPIANDROSTERONE, METHOD OF ITS APPLICATION Download PDF

Info

Publication number
RU2014116566A
RU2014116566A RU2014116566/15A RU2014116566A RU2014116566A RU 2014116566 A RU2014116566 A RU 2014116566A RU 2014116566/15 A RU2014116566/15 A RU 2014116566/15A RU 2014116566 A RU2014116566 A RU 2014116566A RU 2014116566 A RU2014116566 A RU 2014116566A
Authority
RU
Russia
Prior art keywords
dehydroepiandrosterone
microns
content
amount
agent
Prior art date
Application number
RU2014116566/15A
Other languages
Russian (ru)
Other versions
RU2592370C2 (en
RU2592370C9 (en
Inventor
Иван Иванович Дедов
Николай Петрович Гончаров
Гулинара Викторовна Кация
Геннадий Тихонович Сухих
Владимир Васильевич Кураков
Original Assignee
Иван Иванович Дедов
Николай Петрович Гончаров
Гулинара Викторовна Кация
Геннадий Тихонович Сухих
Владимир Васильевич Кураков
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Иван Иванович Дедов, Николай Петрович Гончаров, Гулинара Викторовна Кация, Геннадий Тихонович Сухих, Владимир Васильевич Кураков filed Critical Иван Иванович Дедов
Priority to RU2014116566/15A priority Critical patent/RU2592370C9/en
Publication of RU2014116566A publication Critical patent/RU2014116566A/en
Publication of RU2592370C2 publication Critical patent/RU2592370C2/en
Application granted granted Critical
Publication of RU2592370C9 publication Critical patent/RU2592370C9/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

1. Средство на основе дегидроэпиандростерона, характеризующееся тем, что в состав средства входят микронизированный порошок дегидроэпиандростерона с размерами частиц от 1 до 5 мкм либо его микроэмульсия с размером частиц от 2 до 5 мкм и натуральный биосовместимый наноструктурированный гель хитозана с содержанием дегидроэпиандростерона от 5 до 10 мг в 1 мл.2. Способ применения средства по п. 1 для влагалищного введения менопаузальным женщинам, страдающим вульвовагинальной атрофией, отличающийся тем, что количество ежедневно наносимого средства составляет не более 1 мл с содержанием применяемой минимальной физиологической дозы дегидроэпиандростерона не более 5-10 мг.3. Способ применения средства по п. 1 для чрескожного введения лицам пожилого возраста обоего пола для нормализации стероидного метаболизма и компенсации дефицита дегидроэпиандростерона и тестостерона, отличающийся тем, что количество ежедневно наносимого средства составляет не более 1 мл с содержанием дегидроэпиандростерона не более 5-10 мг.1. The product is based on dehydroepiandrosterone, characterized in that the composition of the product includes micronized dehydroepiandrosterone powder with particle sizes from 1 to 5 microns or its microemulsion with a particle size of 2 to 5 microns and a natural biocompatible nanostructured chitosan gel with a dehydroepiandrosterone content of from 5 to 10 mg in 1 ml. 2. The method of using the agent according to claim 1 for vaginal administration to menopausal women suffering from vulvovaginal atrophy, characterized in that the amount of daily applied agent is not more than 1 ml with a minimum physiological dose of dehydroepiandrosterone of not more than 5-10 mg. 3. The method of using the agent according to claim 1 for transdermal administration of the elderly to both sexes to normalize steroid metabolism and compensate for the deficiency of dehydroepiandrosterone and testosterone, characterized in that the amount of daily applied agent is not more than 1 ml with a dehydroepiandrosterone content of not more than 5-10 mg.

Claims (3)

1. Средство на основе дегидроэпиандростерона, характеризующееся тем, что в состав средства входят микронизированный порошок дегидроэпиандростерона с размерами частиц от 1 до 5 мкм либо его микроэмульсия с размером частиц от 2 до 5 мкм и натуральный биосовместимый наноструктурированный гель хитозана с содержанием дегидроэпиандростерона от 5 до 10 мг в 1 мл.1. The product is based on dehydroepiandrosterone, characterized in that the composition of the product includes micronized dehydroepiandrosterone powder with particle sizes from 1 to 5 microns or its microemulsion with a particle size of 2 to 5 microns and a natural biocompatible nanostructured chitosan gel with a dehydroepiandrosterone content of from 5 to 10 mg in 1 ml. 2. Способ применения средства по п. 1 для влагалищного введения менопаузальным женщинам, страдающим вульвовагинальной атрофией, отличающийся тем, что количество ежедневно наносимого средства составляет не более 1 мл с содержанием применяемой минимальной физиологической дозы дегидроэпиандростерона не более 5-10 мг.2. The method of using the agent according to claim 1 for vaginal administration to menopausal women suffering from vulvovaginal atrophy, characterized in that the amount of daily applied agent is not more than 1 ml with a minimum physiological dose of dehydroepiandrosterone of not more than 5-10 mg. 3. Способ применения средства по п. 1 для чрескожного введения лицам пожилого возраста обоего пола для нормализации стероидного метаболизма и компенсации дефицита дегидроэпиандростерона и тестостерона, отличающийся тем, что количество ежедневно наносимого средства составляет не более 1 мл с содержанием дегидроэпиандростерона не более 5-10 мг. 3. The method of using the tool according to claim 1 for transdermal administration of elderly persons of both sexes to normalize steroid metabolism and compensate for the deficiency of dehydroepiandrosterone and testosterone, characterized in that the amount of daily applied agent is not more than 1 ml with a dehydroepiandrosterone content of not more than 5-10 mg .
RU2014116566/15A 2014-04-24 2014-04-24 Agent based on dehydroepiandrosterone, method for use thereof RU2592370C9 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2014116566/15A RU2592370C9 (en) 2014-04-24 2014-04-24 Agent based on dehydroepiandrosterone, method for use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2014116566/15A RU2592370C9 (en) 2014-04-24 2014-04-24 Agent based on dehydroepiandrosterone, method for use thereof

Publications (3)

Publication Number Publication Date
RU2014116566A true RU2014116566A (en) 2015-10-27
RU2592370C2 RU2592370C2 (en) 2016-07-20
RU2592370C9 RU2592370C9 (en) 2016-08-27

Family

ID=54362699

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014116566/15A RU2592370C9 (en) 2014-04-24 2014-04-24 Agent based on dehydroepiandrosterone, method for use thereof

Country Status (1)

Country Link
RU (1) RU2592370C9 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1021204B1 (en) * 1997-09-26 2005-12-28 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US20090143348A1 (en) * 2007-11-30 2009-06-04 Ahmet Tezel Polysaccharide gel compositions and methods for sustained delivery of drugs
US10080760B2 (en) * 2009-10-27 2018-09-25 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents
SG192114A1 (en) * 2011-01-26 2013-08-30 Allergan Inc Androgen composition for treating an opthalmic condition

Also Published As

Publication number Publication date
RU2592370C2 (en) 2016-07-20
RU2592370C9 (en) 2016-08-27

Similar Documents

Publication Publication Date Title
AR084932A1 (en) OPHTHALMIC COMPOSITION INCLUDING AN ANDROGEN AND ITS USE FOR THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF AN EYE DISEASE RESULTING FROM AN ANDROGENIC DEFICIENCY
RU2009148278A (en) The use of estriol in a low dose
GEP20227407B (en) Contraceptive composition with reduced cardiovascular effects
EA200900491A1 (en) USE OF ESTRADIOL VALERAT OR 17B-ESTRADIOL IN COMBINATION WITH DIENOGEST FOR ORAL TREATMENT TO MAINTAIN AND / OR INCREASE SEXUAL TREATMENT IN THE SPECIAL WOMAN
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
AR079925A1 (en) GEL-BASED COMPOSITIONS AND METHODS TO MANUFACTURE THEM
MY173215A (en) Acetylcysteine compositions and methods of use thereof
PH12017502379A1 (en) Drospirenone-based contraceptive for a female patient affected with excess weight
GEP20227396B (en) Compounds and their uses for alleviating menopause-associated symptoms
RU2011103136A (en) PHARMACEUTICAL COMPOSITION ON THE BASIS OF FINE-GROWED PROGESTERON AND ITS APPLICATIONS
NZ606768A (en) Pharmaceutical compositions and methods of treatment
JP2018527305A5 (en)
PH12014502331B1 (en) Orally available pharmaceutical formulation suitable for improved management of movement disorders
GEP20227395B (en) Compounds and their uses for alleviating menopause-associated symptoms
GB201200858D0 (en) Prebiotic powder composition and uses thereof
NZ751972A (en) Treatment of prurigo nodularis
MX2023005875A (en) Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5h[1,3]dio xolo[4,5-f]indol-7-yl)pyrrole-2,5-dione.
MX2015006370A (en) Herbal supplements and methods of use thereof.
RU2014116566A (en) MEANS ON THE BASIS OF DEHYDROEPIANDROSTERONE, METHOD OF ITS APPLICATION
PE20090805A1 (en) COMBINATION OF DROSPIRENONE AND 17ß-ESTRADIOL AS AN ORAL CONTRACEPTIVE
MX2013012038A (en) Combination of carotenoid, phytooestrogen and vitamin c for moisturizing the skin.
MX346467B (en) A composition comprising at least one alginate for use in treatment and/or prevention of overweight.
MX2019013851A (en) Theacrine-based supplement and method of use thereof in a synergistic combination with caffeine.
WO2017100378A3 (en) Vaginal inserted estradiol pharmaceutical compositions and methods
MX2016011801A (en) Low-dose estradiol cream.

Legal Events

Date Code Title Description
TH4A Reissue of patent specification
MM4A The patent is invalid due to non-payment of fees

Effective date: 20180425

NF4A Reinstatement of patent

Effective date: 20190218